Status:
COMPLETED
12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.
Lead Sponsor:
Pfizer
Conditions:
Smoking Cessation
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to measure the safety and efficacy of four dosing strategies of CP-526,555 for 12 weeks compared with placebo for smoking cessation. Post-treatment follow-up of smoking sta...
Eligibility Criteria
Inclusion
- Subjects must have smoked on average of at least ten cigarettes per day during the past year
- Subjects must have no period of abstinence greater than three months in the past year
Exclusion
- Subjects with any history of clinically significant cardiovascular disease
- Uncontrolled hypertension
Key Trial Info
Start Date :
September 1 2001
Trial Type :
INTERVENTIONAL
End Date :
October 1 2002
Estimated Enrollment :
625 Patients enrolled
Trial Details
Trial ID
NCT00150254
Start Date
September 1 2001
End Date
October 1 2002
Last Update
June 4 2007
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Los Angeles, California, United States
2
Pfizer Investigational Site
San Bernardino, California, United States
3
Pfizer Investigational Site
Upland, California, United States
4
Pfizer Investigational Site
West Covina, California, United States